CFDE Data Portal | Search PTGES2-DT

	Label	Description
	PTGES2-DT Gene (Entity type)	ENSG00000232850 - PTGES2 divergent transcript
	GSE195663 cisplatin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE238213 dopamine 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE248769 1 V 0 SORAFENIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE113655 phenol 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE196035 GSE196037 MEN1 inhibition 5 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 7 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE165548 gemcitabine 2 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE228263 FDX1 overexpression SU-DHL-4 Elesclomol 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE228263 elesclomol SU-DHL-4 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS

PTGES2-DT

ENSG00000232850 - PTGES2 divergent transcript

GSE195663 cisplatin 0 v 1 human up

A Gene Set from LINCS

GSE238213 dopamine 1 v 0 human dn

A Gene Set from LINCS

GSE248769 1 V 0 SORAFENIB HUMAN UP

A Gene Set from LINCS

GSE113655 phenol 1 v 2 human dn

A Gene Set from LINCS

GSE196035 GSE196037 MEN1 inhibition 5 v 11 human dn

A Gene Set from LINCS

GSE195663 cisplatin 7 v 1 human up

A Gene Set from LINCS

GSE165548 gemcitabine 2 v 5 human up

A Gene Set from LINCS

GSE228263 FDX1 overexpression SU-DHL-4 Elesclomol 0 v 1 human dn

A Gene Set from LINCS

GSE228263 elesclomol SU-DHL-4 0 v 1 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.